Hospital

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

It remains a challenge to understand how to stratify risk of liver diseases before they have reached the advanced stage.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Relatives who attend low-intensity coaching and monitoring meetings increase individuals’ ability to manage the disease.

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

Five crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

A patient with juvenile dermatomyositis experienced aseptic meningitis brought on by intravenous immunoglobulin and recovered fully with no neurological effects.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

In recent decades, clinical trials have grown increasingly restrictive and exclusive, which has impacted the inclusivity and diversity of selected trial participants.

Clinicians should consider potential aspiration of illicit drug packets that were swallowed or inserted into the body.

The presence of CD8+ cells may help predict outcomes for patients administered immune checkpoint inhibitors.

Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and triglycerides.

Booster shots updated for the Omicron variant BA.4 and BA.5 lineages cleared for children 6 months through 4 years of age.

Study finds urgent need for aggressive expansion of pre-exposure prophylaxis among people who inject drugs to reduce the spread of HIV.

RSVpreF produced vaccine efficacy of 66.7% against respiratory syncytial virus-associated lower respiratory tract illness in older adults.

Dr. Jaclyn Boyle is assistant dean for Student Success and associate professor of Pharmacy Practice at Northeast Ohio Medical University.

Mice receiving prophylactic recombinant factor FVIII and intravenous immunoglobulin for hemophilia A had reduced anti-FVIII antibodies versus mice who received FVIII only.

Both vaccine hesitancy and antivax beliefs are largely fueled by inaccurate reports of adverse effects from vaccines, a new study finds.

Study finds textured breast implants do not increase the risk of anaplastic large-cell lymphoma, which has grown in incidence since 2008.

Implants could produce and deliver monoclonal anti-HIV antibody therapy for at least 1 year.

PHP shows promise extending survival in patients with inoperable intrahepatic cholangiocarinomas or extrahepatic cholangiocarinoma with liver metastases.

Kalin Clifford, associate professor in the Geriatrics Division at Texas Tech University Health Sciences Center in the Jerry H. Hodge School of Pharmacy, discusses the potential benefits of herbal supplements for dementia care.

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.